| AK2 | Adenylate kinase 2 |
| AML | Acute myeloid leukemia |
| ALL | Acute lymphoblastic leukemia |
| AR | Androgen receptor |
| AROS | Active regulator of SIRT1 |
| ASH1L | ASH1-like |
| ATRA | All-trans retinoic acid |
| BET | Bromodomain and extraterminal |
| CN | Cytogenetically normal |
| DDR | DNA damage response |
| DSB | Double-strand break |
| EMT | Epithelial–mesenchymal transition |
| ERα | Estrogen receptor alpha |
| G6PD | Glucose-6-phosphate dehydrogenase |
| HCC | Hepatocellular carcinoma |
| HGSC | High-grade serous carcinoma |
| HK2 | Hexokinase 2 |
| H3K36 | Histone lysine 36 |
| H3K36me1 | Histone lysine 36 monomethylation |
| H3K36me2 | Histone lysine 36 dimethylation |
| H3K36me3 | Histone lysine 36 trimethylation |
| HMG | High mobility group |
| HNSCC | Head and neck squamous cell carcinoma |
| HR | Homologous recombination |
| IRF3 | Interferon regulatory factor 3 |
| JHDM | Jumonji C (JmjC) domain-containing histone demethylase |
| LCA | Laryngeal cancer |
| LUAD | Lung adenocarcinoma |
| LUSC | Lung squamous cell carcinoma |
| MLL1 | Mixed lineage leukemia 1 |
| NHEJ | Non-homologous end joining |
| NSL | Non-specific lethal |
| NUP98 | Nucleoporin 98 |
| NSD | Nuclear receptor-binding SET domain-containing protein |
| NSRP1 | Nuclear speckle splicing regulatory protein 1 |
| PHD | Plant homeodomain |
| PROTAC | PROteolysis-Targeting Chimera |
| PWWP | Proline-tryptophan-tryptophan-proline |
| SAM | S-adenosylmethionine |
| SET | Su(var)3-9, enhancer of zeste and trithorax |
| SETMAR | SET domain and mariner transposase fusion gene-containing |
| SMYD2 | SET and MYND domain-containing 2 |
| TCGA | The Cancer Genome Atlas |
| TMB | Tumor mutation burden |
| TNBC | Triple-negative breast cancer |
| VEGF-A | Vascular endothelial growth factor-A |